Tower Research Capital (TRC)’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Tower Research Capital (TRC)’s Portfolio QNTM Stock Details QNTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$343	Buy	+71	New	+$320	﹤0.01%	4903
2025 Q3	–	Sell	-544	Closed	-$11K	–	5716
2025 Q2	$11K	Sell	544 -2,651	-83%	-$32.7K	﹤0.01%	3925
2025 Q1	$24.6K	Buy	+3,195	New	+$18.4K	﹤0.01%	2777

Other funds holding QNTM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Tower Research Capital (TRC)'s QNTM Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q1 2026: 71 shares worth $343. The stake represents ﹤0.01% of the portfolio and ranks #4903 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in QNTM as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in QNTM in Q1 2025 and has held it in 3 quarters since. The position peaked at $24.6K in Q1 2025. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

Tower Research Capital (TRC) held 71 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $343 as of Q1 2026.
Quantum Biopharma Class B Subordinate Voting Shares was a new Tower Research Capital (TRC) position in Q1 2026.
Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4903 holding.
Tower Research Capital (TRC) first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2025 and has held it in 3 quarters since.
Tower Research Capital (TRC)'s Quantum Biopharma Class B Subordinate Voting Shares position peaked at $24.6K in Q1 2025.
25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.